Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2024-04-23 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
2023年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2023 年年度报告摘要" which translates to "2023 Annual Report Summary". It contains detailed financial data for the year 2023, including total assets, net profit, earnings per share, and other key financial indicators. It also includes company business descriptions, product lines, shareholder information, bond information, and important corporate events during the year. The document is over 14,000 characters long, indicating it is a substantive report rather than a brief announcement. The presence of audited financial data and comprehensive business and financial information aligns with the characteristics of an Annual Report (10-K). There is no indication that this is merely an announcement or a certification, so it should not be classified as RPA or RNS. Therefore, the document is best classified as an Annual Report (10-K). FY 2023
2024-04-23 Chinese
关于提请股东大会授权董事会办理以简易程序向特定对象发行A股股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding a proposal to the shareholders' meeting to authorize the board of directors to issue A-shares to specific investors via a simplified procedure. It details the terms of the proposed share issuance, including the amount, pricing, issuance method, authorization period, and related procedural authorizations. The document is a formal announcement of a capital raising plan requiring shareholder approval, not the actual issuance report or financial statements. It does not contain financial results or detailed financial data but rather a capital/financing update about a planned share issuance. The document length is 2824 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-04-23 Chinese
2023年年度审计报告
Audit Report / Information Classification · 100% confidence The document contains a detailed audit report including audit opinions, basis for audit opinions, key audit matters, and extensive financial statement notes. It references the audit of financial statements for the fiscal year ending December 31, 2023, and includes detailed accounting policies, financial data, and disclosures. The presence of an audit opinion section, detailed audit procedures, and extensive financial statement notes indicates this is a standalone audit report rather than a full annual report or other filing. The document length (15,000 characters) and content confirm it is not a brief announcement or certification. Therefore, the document is best classified as an Audit Report / Information (AR). FY 2023
2024-04-23 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 24th meeting of the third board of directors of Zhejiang Tailin Biotechnology Co., Ltd. It includes approvals of various reports such as the 2023 Annual Report, 2024 Q1 Report, 2023 Board Work Report, 2023 General Manager Work Report, profit distribution proposals, financial statements, audit reports, internal control reports, remuneration plans, and other corporate governance matters. The document also mentions that these reports and proposals have been or will be submitted to the 2023 Annual General Meeting for approval. The document is not the reports themselves but a formal announcement of the board meeting decisions and approvals. It references the full reports being available on the official disclosure website. The document length is 6469 characters, which is substantial but the content is clearly a board meeting resolution announcement rather than the full reports. Therefore, this document fits best into the category of Board/Management Information (MANG), as it announces board meeting resolutions including management and governance decisions.
2024-04-23 Chinese
关于2023年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm Tianjian for the year 2023. It details the qualifications, independence, quality management, and audit work plan of the accounting firm engaged by Zhejiang Tailin Biotechnology Co., Ltd. The content focuses on the audit firm's compliance, quality control, and audit execution rather than presenting the company's financial statements or audit opinions themselves. The document length is 2975 characters, which is relatively short and reads like an assessment or report on the auditor's performance rather than a full audit report or annual report. There is no presentation of financial data or audit results, only an evaluation of the auditor's work. This fits the category of an Audit Report / Information (AR) as it is a standalone audit-related report about the auditor's performance and compliance, not the full annual report or financial statements. FY 2023
2024-04-23 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 16th meeting of the third Supervisory Board of Zhejiang Tailin Biotechnology Co., Ltd. It includes approvals of various reports such as the 2023 Annual Report, 2024 Q1 Report, 2023 Supervisory Board Work Report, 2023 Financial Statements, 2023 Audit Report, internal control self-evaluation report, and other governance and financial matters. The document repeatedly states that the full reports are published on the official disclosure website (cninfo.com.cn) and that these resolutions will be submitted to the 2023 Annual General Meeting for approval. The document itself does not contain the full reports or substantive financial data but is a formal announcement of the Supervisory Board's review and approval of these reports and proposals. Given the nature of the content—meeting resolutions and approvals by the Supervisory Board—and the absence of the full reports or detailed financial data, this document fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length is 4024 characters, which is relatively short and consistent with an announcement rather than a full report.
2024-04-23 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.